AGEN/ 07/13/2026 · 3:40 PM Agenus Secures Up to $340M to Fund Pivotal Phase 3 ROBBIN Trial in Neoadjuvant Colon Cancer H.C. Wainwright boosts Agenus’ price target to $30 from $23, reiterating a Buy rating.
